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 Outcome of Surgical or Endovascular 
Treatment of Giant Intracranial Aneurysms, 
with Emphasis on Age, Aneurysm Location, 
and Unruptured Aneuryms – A Systematic 
Review and Meta-Analysis 
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pared to 81.2% (75.3–86.1) in the separate analysis of unrup-
tured GIA. For each year added to patient age, PGO de-
creased by 0.8%, both for all GIA and unruptured GIA. For all 
GIA, surgical treatment resulted in a PGO of 80.3% (95% CI 
76.0–84.6) compared to 84.2% (78.5–89.8, p = 0.27) after en-
dovascular treatment. In unruptured GIA, PGO was 79.7% 
(95% CI 71.5–87.8) after surgical treatment and 84.9% (79.1–
90.7, p = 0.54) after endovascular treatment. PGO was lower 
in high quality studies and in studies presenting aggregate 
instead of individual patient data. In unruptured GIA, the OR 
for good treatment outcome was 5.2 (95% CI 2.0–13.0) at the 
internal carotid artery compared to 0.1 (0.1–0.3, p < 0.1) in 
the posterior circulation. Patient sex, FU-T and prevalence of 
ruptured GIA were not associated with PGO.  Conclusions: 
We found that the chances of good outcome after surgical 
or endovascular GIA treatment mainly depend on patient 
age and aneurysm location rather than on the type of treat-
ment conducted. Our analysis may inform future research on 
GIA.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: Designing treatment strategies for unrup-
tured giant intracranial aneurysms (GIA) is difficult as evi-
dence of large clinical trials is lacking. We examined the out-
come following surgical or endovascular GIA treatment fo-
cusing on patient age, GIA location and unruptured GIA. 
 Methods: Medline and Embase were searched for studies 
reporting on GIA treatment outcome published after  January 
2000. We calculated the proportion of good outcome (PGO) 
for all included GIA and for unruptured GIA by meta-analysis 
using a random effects model.  Results: We included 54 stud-
ies containing 64 study populations with 1,269 GIA at a me-
dian follow-up time (FU-T) of 26.4 months (95% CI 10.8–42.0). 
PGO was 80.9% (77.4–84.4) in the analysis of all GIA com-
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 Introduction 
 Increasing intracranial aneurysm (IA) size is one of the 
main risk factors for aneurysm rupture with subsequent 
morbidity and mortality [1–5] . Guidelines therefore rec-
ommend conservative treatment for unruptured small 
IA, with cutoffs ranging between 7 and 13 mm in diam-
eter and surgical or endovascular treatment for larger an-
eurysms  [2, 3, 6–8] . Surgical and endovascular treatment 
have become common for unruptured large IA and are 
also increasingly conducted in unruptured giant IA 
(GIA), which are defined as the largest IA with a diameter 
 ≥ 25 mm and are known for rupture rates exceeding 10% 
per year  [1, 9] . While the treatment of unruptured large 
IA is widely accepted, the treatment of unruptured GIA 
remains controversial due to reports on poor outcome 
and overall cost ineffectiveness  [1, 10] .
 Accurate estimates on surgical or endovascular GIA 
treatment outcome are difficult to establish mainly due to 
the low prevalence of the disease since GIA only make up 
about 2–5% of all IAs  [1, 3] . Multicenter prospective ap-
proaches have so far only been able to examine GIA treat-
ment outcome as a marginal byproduct of cohorts that 
predominantly contain data on non-giant IAs  [1] .
 Since GIA are associated with the worst outcome and 
the highest cost of all IAs, there is a need for robust scien-
tific evidence exclusively focusing on this subgroup of 
IAs. We conducted a systematic review and meta-analysis 
of recent literature on surgical or endovascular GIA treat-
ment outcome. The main aim was to examine GIA treat-
ment outcome with emphasis on patient age, GIA loca-
tion, the type of treatment and unruptured GIA.
 Methods 
 Search Strategy and Selection Criteria 
 The analysis was designed according to the PRISMA statement 
 [11] . We searched Medline and Embase for studies reporting on 
outcome of surgical or endovascular GIA treatment. The search 
was conducted on March 5, 2014, and included studies published 
between January 2000 and present to reflect the current state of 
GIA therapy. We used the MeSH term ‘intracranial aneurysm * ’ 
with subheadings ‘therapy’, ‘surgery’, ‘mortality’ and ‘disease man-
agement’. We added the following keywords:
 – [AND] giant OR fusiform OR saccular OR large OR ruptured 
OR unruptured OR complex 
 – [AND] management OR treatment OR endovascular OR sur-
gical OR clip * OR coil * OR stent * OR outcome OR follow-up 
OR result 
 The following inclusion criteria were defined. Publications had 
to be in English. Patients had to be at least 18 years old. If a study 
also included pediatric patients (<18 years), only data on adult pa-
tients were included. Treatment outcome had to be reported for at 
least 4 IA patients to avoid case reports of anecdotal character. 
Data on GIA had to be distinguishable from those on non-giant 
IA. Treatment outcome had to be reported either by using scoring 
systems such as modified Rankin score (mRS) or Glasgow out-
come score (GOS) or by describing the patient’s clinical status in 
sufficient detail for a clear interpretation. We also screened refer-
ence lists of included publications and the personal databases of 
the principal investigators (J.D. and P.V.). If uncertainties oc-
curred regarding the type of data presentation, we contacted the 
authors and asked them to provide the data in a way that made 
inclusion possible. If relevant data, for example, treatment out-
come or GIA location, were missing for a case, the entire case was 
excluded from the analysis. Principal reviewers were J.D. and N.M. 
They independently searched the literature and screened titles and 
abstracts. In case of disagreement, the details were discussed until 
an agreement was reached. Both reviewers then conducted a full 
text screening of all eligible articles.
 Data Extraction 
 Standardized forms were used by both reviewers to extract the 
following data: name of study author, year of publication, type of 
study design, time frame in which the study was conducted, total 
number of patients, number of patients with GIA, patient age and 
sex, prevalence of ruptured GIA, GIA location, type of treatment, 
follow-up time (FU-T), number of cases lost to follow-up, type of 
outcome description (GOS, mRS or no score), number of cases 
with good or bad outcome and type of data presentation (aggregate 
or individual).
 Study quality was assessed according to the following catego-
ries: outcome described by score (1 point) or neurological symp-
toms (0 points), study design prospective (1 point) or retrospective 
(0 points), cases lost to follow-up less than 3% (1 point) or more 
than 3% (0 points). Studies with 3 points were graded high quality, 
and studies with less than 3 points lower quality.
 Good outcome was classified as GOS 4–5 or mRS 0–2 or im-
provement or no aggravation of clinical symptoms compared to 
pre-treatment status  [12] . GIA location was categorized as internal 
carotid artery (ICA, including the posterior communicating ar-
tery), middle cerebral artery (MCA), anterior cerebral artery 
(ACA, including the anterior communicating artery) and poste-
rior circulation (including the vertebral, basilar, cerebellar and 
posterior cerebral arteries). The type of treatment was divided into 
surgical, endovascular and combined surgical/endovascular. For 
quality control, a third reviewer (S.G.) also completed the data ex-
traction form for 10 studies randomly selected from the pool of 
eligible studies.
 Statistical Analysis 
 The primary end point was the proportion of good outcome 
(PGO) interpreted as probability value and displayed as percent-
age with corresponding 95% CI. The PGO was calculated as the 
number of GIA cases with good outcome divided by the total num-
ber of included GIA cases. Meta-analysis was conducted using a 
random effects model including a grand mean for PGO, the devia-
tion of the study’s true PGO from the grand mean and the devia-
tion of the study’s observed PGO from the study’s true PGO (sam-
pling error). Using this model, the mean PGO was estimated by a 
weighted mean over the single studies with assigned weights as 
inverse of the sum of within-study variance and estimated hetero-
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geneity variance. The variance of the distribution of the deviations 
of the study’s true PGOs from the grand mean was denoted by τ 2 
(heterogeneity variance), which was calculated using the DerSimo-
nian method  [13] . The heterogeneity of proportions was analyzed 
using a Q-statistic test, measuring weighted squared deviations. 
We used the I 2 -statistic to estimate the proportion of the observed 
variance in PGO. Sub-group meta-analyses were conducted for the 
following categories: patient age and sex, type of treatment, study 
quality, type of outcome description, mean FU-T (shorter than or 
equal to and longer than the median of all mean FU-Ts), preva-
lence of ruptured GIA (0, <33.3 or  ≥ 33.3%) and type of patient data 
presentation (aggregate or individual). Meta-regression was con-
ducted to explore the heterogeneity of PGO in more detail and 
adjust PGO by including mean age as covariate for 4 models using 
patient sex, type of treatment, prevalence of ruptured GIA and the 
type of patient data presentation as factors.
 For the separate evaluation of individual patient data, we used 
univariate cross table analysis and subsequent hierarchical logistic 
regression analysis to examine the relationship between the odds 
for good outcome and the variables GIA location, patient age and 
type of treatment. Patient age was divided into 4 quartiles: <45, 
45–54, 55–63, and >63 years. We used multilevel models with the 
covariates patient age and type of treatment to calculate adjusted 
OR for good outcome for each GIA location taking into account 
clustering of patients within different study populations. We ap-
plied a mixed effects model including the random study effect as a 
G-side effect.
 Since outcome data for ruptured and unruptured GIA were not 
separable in all studies, we used 3 different approaches for data 
analysis. The first approach examined the PGO for the entire data 
stock by meta-analysis, including both ruptured and unruptured 
GIA. The second approach exclusively examined unruptured GIA 
presented as aggregate or individual patient data, again using me-
ta-analysis. For this, we excluded all ruptured GIA cases from stud-
ies presenting individual patient data and all studies presenting 
aggregate patient data that did not differentiate between outcome 
data for ruptured and unruptured GIA. The third approach exclu-
sively analyzed unruptured GIA presented as individual patient 
data applying hierarchical logistic regression within a multilevel 
model.
 For statistical analysis, we used SAS 9.2 (SAS Institute Inc., 
Cary, N.C., USA) and OpenMeta[Analyst] for Windows 7 (Brown 
University, Providence, R.I., USA)  [14] .
 Results 
 The inclusion criteria were met by 54 studies with 64 
study populations and 1,269 GIA ( fig. 1 )  [1, 15–67] . Pa-
tient data description was aggregate in 15 study popula-
tions (854 GIA)  [1, 15–26] and individual in 49 study 
populations (415 GIA)  [27–67] .  Table  1 displays the 
2,545 studies identified through
Medline search
1,597 studies identified through
Embase search
1,102 duplicates excluded
2,465 excluded by title screening
47 excluded by abstract screening
3,040 studies selected for
title screening
575 studies selected for
abstract screening
528 studies selected for
full text screening
54 studies included with
1,269 GIA in 64 study populations
4 studies included
from other sources
478 excluded by full text screening
 Fig. 1. Literature search. 
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Table 1.  Characteristics of 54 studies reporting on GIA treatment outcome
Study Mid-year 
of study
Study 
design
Type of 
treatment
Number 
of GIA 
included
Sex, 
female, 
%
Mean 
age, 
years
 Reported on:
prev alence of 
ruptured GIA
individual 
patient data
ISUIA [1] 1995 P S/E 124 N/A 54.5 Yes No
Nanda et al. [15] 2000 R S 57 71 50.6 Yes No
Sughrue et al. [16] 2003 R S 140 64 54.0 Yes No
Kolasa et al. [17] 1997 R S/E 20 85 50.0 No No
Sharma et al. [18] 2001 R S 177 N/A N/A Yes No
Lozier et al. [19] 1993 P S 16 63 54.9 Yes No
Osawa et al. [20] 1993 R S 12 N/A N/A Yes No
Qi et al. [21] 2001 R S 155 48 39.3 Yes No
Li et al. [22] 2007 R S 4 N/A No No No
Cantore et al. [23] 1997 R S 99 55 48.0 Yes No
Nakase et al. [24] 1999 R S 26 88 54.5 Yes No
Romani et al. [25] 2002 R S 8 N/A N/A No No
Orz et al. [26] 1991 R S 16 N/A N/A Yes No
Jahromi et al. [27] 2004 P E 39 77 60.9 Yes Yes
Lubicz et al. [28] 1997 R E 12 25 50.8 Yes Yes
Li et al. [29] 2001 R E 16 56 48.1 Yes Yes
Ciceri et al. [30] 1995 R E 4 50 48.0 Yes Yes
Uda et al. [31] 1994 R E 4 67 53.5 Yes Yes
Kalani et al. [32] 1997 R S/C 12 27 43.7 Yes Yes
Hauck et al. [33] 2004 R E 10 80 62.1 Yes Yes
de Barros et al. [34] 2008 R E 6 14 58.9 Yes Yes
Ha and Jang [35] 2004 R E 9 78 59.2 Yes Yes
Waldron et al. [36] 2004 R S 6 33 59.2 Yes Yes
Seo et al. [37] 2002 R S 4 25 36.5 Yes Yes
Sluzewski et al. [38] 1997 R E 13 56 52.4 Yes Yes
Zhang et al. [39] 1998 P S 7 57 52.9 Yes Yes
Sekhar et al. [40] 1997 R S 8 88 56.5 Yes Yes
Raphaeli et al. [41] 2007 R E 5 40 58.0 Yes Yes
Biondi et al. [42] 2001 R E 6 67 43.3 Yes Yes
Meckel et al. [43] 2010 R E 8 63 55.1 Yes Yes
Lubicz et al. [44] 2009 P E 4 75 61.5 Yes Yes
Iihara et al. [45] 2003 R S/E/C 9 30 52.2 Yes Yes
Clarençon et al. [46] 2002 R E 12 29 43.1 Yes Yes
Siddiqui et al. [47] 2010 R E 7 43 55.4 Yes Yes
Nakajima et al. [48] 2007 R S 11 64 47.5 Yes Yes
Skrap et al. [49] 2005 R S 15 80 51.6 Yes Yes
Kubo et al. [50] 2000 R S 11 91 60.2 Yes Yes
Miyamoto et al. [51] 2006 R S/C 6 50 45.7 Yes Yes
Lownie et al. [52] 1985 R S/E 13 21 52.8 Yes Yes
Van Doormaal et al. [53] 2001 R S 32 75 54.1 Yes Yes
Nakajima et al. [54] 2007 R S 5 40 55.4 Yes Yes
Lv et al. [55] 2006 R E 32 68 48.5 Yes Yes
Pumar et al. [56] 2009 R E 6 N/A N/A Yes Yes
Velat et al. [57] 1999 P S 6 91 62.8 Yes Yes
Biondi et al. [58] 2003 R E 4 50 55.5 Yes Yes
Kellner et al. [59] 1998 R S 6 67 43.5 Yes Yes
Kalani et al. [60] 2002 R S/C 8 13 52.6 Yes Yes
Lubicz et al. [61] 1997 R E 17 59 40.0 Yes Yes
Ponce et al. [62] 2000 R S 8 44 61.3 Yes Yes
Shi et al. [63] 1998 R C/E 9 22 56.4 Yes Yes
Ewald et al. [64] N/A R S/C 8 N/A N/A Yes Yes
Hallacq et al. [65] 1994 R E 5 40 43.6 Yes Yes
Tan et al. [66] 2006 R E 5 20 48.4 Yes Yes
Weber et al. [67] 2002 R E 7 100 50.6 Yes Yes
 P = Prospective; R = retrospective; S = surgical; E = endovascular; C = combined; N/A = not available.
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study characteristics. We included 27 study populations 
with endovascular treatment (297 GIA)  [1, 17, 27–31, 
33–35, 38, 41–47, 52, 55, 56, 58, 61, 63, 65–67] , 31 study 
populations with surgical treatment (955 GIA)  [1, 15–26, 
32, 36, 37, 39, 40, 45, 48–54, 57, 59, 60, 62, 64] and 6 study 
populations with combined treatment (17 GIA)  [32, 45, 
51, 60, 63, 64] . The patients’ clinical status was measured 
by GOS in 26 study populations (844 GIA)  [15–18, 20–
22, 37–41] , by mRS in 25 study populations (217 GIA) 
 [1, 19, 42–60] and by description of neurological symp-
toms in 13 study populations (208 GIA)  [23–26, 61–67] . 
Data of 6 study populations (190 GIA) were rated high 
quality  [1, 19, 27, 39, 44] while those of the remaining 58 
study cohorts (1,079 GIA) were rated lower quality. In-
formation on whether GIA were ruptured or unruptured 
was available in 60 study populations (1,202 GIA)  [1, 15, 
16, 18–21, 23, 24, 26–67] . The prevalence of ruptured 
GIA was  ≥ 33.3% in 15 study populations (511 GIA)  [15, 
18, 20, 21, 28, 31, 34–38, 42, 52, 53, 57] , <33.3% in 18 
study populations (396 GIA)  [16, 19, 23, 27, 29, 32, 39, 
43, 48, 50, 51, 55, 58, 61, 63–66] and 0% in 27 study pop-
ulations (295 GIA)  [1, 24, 26, 30, 32, 33, 40, 41, 44–47, 
49, 51, 52, 54, 56, 59, 60, 62–64, 67] . The weighted me-
dian FU-T was 26.4 months (95% CI 10.8–42.0).
 Overall PGO for all GIA of all study populations was 
80.9% (95% CI 77.4–84.4) ( fig. 2 ). There was a significant 
association between PGO and patient age (p < 0.01). For 
any year added to mean patient age, PGO decreased by 
0.8%. This relationship existed in all 3 treatment groups. 
We adjusted all further analyses for patient age.  Table 2 
displays the PGO for the type of treatment, study quality, 
type of outcome description, FU-T, type of patient data 
description and prevalence of ruptured GIA.
 With the surgical study populations as the reference 
group, there was no significant difference in PGO be-
tween surgical (80.3%, 95% CI 76.0–84.6) and endovas-
cular study populations (84.2%, 95% CI 78.5–89.8, p = 
0.27). The PGO for combined treatment study popula-
tions differed significantly (49.9%, 95% CI 28.4–71.5%, 
p  = 0.01). However, the total number of patients with 
combined treatment was comparably low (n = 17).
 When high quality study populations were defined as 
the reference group, their PGO (70.0%, 95% CI 60.9–
79.2) was significantly lower than that of studies of low-
er quality (83.6%, 95% CI 77.7–90.0, p = 0.01). We also 
identified a significant difference in PGO depending on 
whether results were presented as aggregate patient data 
(75.3%, 95% CI 69.3–81.3) or as individual patient data 
(83.8, 95% CI 79.6–88.1, p < 0.01). PGO was not associ-
ated with patient sex, type of outcome description, FU-T 
or prevalence of ruptured GIA. We found substantial 
overall heterogeneity (I 2  = 48%) in the analysis of PGO, 
which suggests relevant differences in study popula-
tions. For the separate analysis of treatment outcome of 
unruptured GIA, we included 455 unruptured GIA from 
51 study populations  [1, 22, 27–67] , presented as aggre-
gate patient data in 3 study populations (128 GIA)  [1, 
22] and as individual patient data in 48 study popula-
tions (327 GIA)  [27–67] . Endovascular treatment was 
conducted in 26 study populations (246 GIA)  [1, 27–31, 
33–35, 38, 41–47, 52, 55, 56, 58, 61, 63, 65–67] , surgical 
treatment in 20 study populations (196 GIA)  [1, 22, 32, 
36, 37, 39, 40, 45, 48–54, 57, 59, 60, 62, 64] and combined 
treatment in 5 study populations (13 GIA)  [32, 45, 51, 
60, 63] . For all unruptured GIA taken together, the PGO 
was 81.2% (95% CI 75.3–86.1). Patient age was signifi-
cantly associated with PGO, which decreased by 0.8% 
per year added to patient age (p = 0.01).  Table 2 displays 
the PGO for unruptured GIA. After adjusting for patient 
age, we identified no difference in PGO between surgical 
(79.7%, 95% CI 71.5–87.8, reference group) and endo-
vascular study populations (84.9%, 95% CI 79.1–90.7, 
p = 0.54). For the small group of unruptured GIA with 
combined treatment (13 GIA), PGO was significantly 
lower (50.3%, 95% CI 25.6–75.0, p = 0.02). High quality 
study populations displayed lower PGO (68.1%, 95% CI 
58.7–77.4) than study populations of lower quality 
(84.3%, 95% CI 76.5–92.8, p = 0     ·      01). We also found 
lower PGO in study populations with aggregate patient 
data (62.5%, 95% CI 54.2–70.9) than in study popula-
tions with individual patient data (84.1%, 95% CI 79.7–
88.7, p < 0.01). There was no association between PGO 
and patient sex, type of outcome description or FU-T.
 To examine the PGO of unruptured GIA in more de-
tail, we conducted an analysis of only individual patient 
data on unruptured GIA. For this, we included 324 un-
ruptured GIA from 48 study populations  [27–67] . Treat-
ment was endovascular in 192 GIA (25 study popula-
tions)  [27–31, 33–35, 38, 41–47, 52, 55, 56, 58, 61, 63, 
65–67] , surgical in 119 GIA (18 study populations)  [32, 
36, 37, 39, 40, 45, 48–54, 57, 59, 60, 62, 64] and combined 
in 13 GIA (5 study populations)  [32, 45, 51, 60, 63, 64] . 
Median FU-T was 16.0 months (95% CI 14.0–20.0). One 
hundred fifty-three unruptured GIA (47.2%) were locat-
ed at the ICA, 43 (13.3%) at the MCA, 17 (5.2%) at the 
ACA and 111 (34.3%) in the posterior circulation. The 
distribution of the types of GIA treatment (endovascular/
surgical/combined) was 68.5/31.5/0% at the ICA, 
12.8/71.8/15.4% at the MCA, 31.3/68.7/0% at the ACA 
and 66.0/27.4/6.6% in the posterior circulation.  Table 3 
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 Fig. 2. PGO of all study cohorts. S = Surgi-
cal treatment; E = endovascular treatment; 
C = combined treatment. 
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Table 2.  PGO for all 64 study populations and for unruptured GIA
All GIA (64 study 
populations, 1,269 GIA)
Unruptured GIA (51 study 
populations,  455 GIA)
PGO p value PG O p value
Entire study cohort 80.9 (77.4–84.4) – 81.2 (75.3–86.1) –
Type of treatment
Surgical treatment 80.3 (76.0–84.6) ref. 79.7 (71.5–87.8) ref.
Endovascular treatment 84.2 (78.5–89.8) 0.27 84.9 (79.1–90.7) 0.54
Combined treatment 49.9 (28.4–71.5) 0.01 50.3 (25.6–75.0) 0.02
Study quality
High 70.0 (60.9–79.2) ref. 68.1 (58.7–77.4) ref.
Lower 83.6 (77.7–90.0) 0.01 84.3 (76.5–92.8) 0.01
Outcome described by
GOS 83.2 (78.8–87.6) ref. 81.0 (73.0–89.0) ref.
mRS 77.6 (70.0–85.2) 0.40 78.8 (70.7–86.8) 0.50
Neurological symptoms 86.8 (81.8–91.7) 0.34 91.5 (84.7–98.4) 0.86
FU-T
<Median FU-T 80.2 (73.9–86.5) ref. 80.0 (72.6–87.5) ref.
≥Median FU-T 86.8 (82.6–91.1) 0.26 84.1 (76.8–91.4) 0.52
Patient data presentation
Aggregate 75.3 (69.3–81.3) ref. 62.5 (54.2–70.9) ref.
Individual 83.8 (79.6–88.1) <0.01 84.1 (79.7–88.7) <0.01
Prevalence of ruptured GIA, %
0 79.6 (72.1–87.1) ref.
<33 84.9 (79.4–90.4) 0.29
≥33 82.4 (77.7–87.0) 0.18
 Data are adjusted for mean patient age and presented in % with 95% CI. FU-T = Follow-up time; ref. = refer-
ence group.
Table 3.  PGO and OR for good outcome after treatment of unruptured GIA with individually described patient 
data
PGO OR (95% CI) p value
Type of treatment
Endovascular (192 GIA) 84.4 ref. 0.16
Surgical (119 GIA) 80.7 0.55 (0.12–2.04)
Combined (13 GIA) 53.8 0.07 (0.01–1.53)
GIA location
ICA (including PcomA; 153 GIA) 92.8 ref. <0.01
ACA (including AcomA; 17 GIA) 82.4 0.41 (0.07–2.62)
MCA (43 GIA) 83.7 0.85 (0.19–3.87)
Posterior circulation (111 GIA) 65.8 0.12 (0.05–0.31)
Patient age, years
<45 (81 GIA) 90.4 ref. 0.03
45–54 (81 GIA) 85.3 0.62 (0.21–1.83)
55–63 (81 GIA) 81.3 0.45 (0.16–1.27)
>63 (81 GIA) 68.5 0.22 (0.08–0.62)
 We included 324 GIA from 48 study populations in this analysis [27–67]. PGO is given as mean %. OR are 
presented with 95% CI and p value. PcomA = Posterior communicating artery; ref. = reference.
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displays the PGO and OR for good outcome for the type 
of GIA treatment, GIA location and patient age. Both 
PGO and OR for good outcome were significantly lower 
for unruptured GIA in the posterior circulation than for 
those of all other locations (p < 0.01). Again, we found an 
association between patient age and PGO (p = 0.03). After 
adjusting for patient age and the location of unruptured 
GIA, there was no difference in PGO between surgical 
(80.7%, 95% CI 72.9–89.3, reference group), endovascu-
lar (84.4%, 95% CI 78.6–90.1) or combined treatment 
study populations (53.8%, 95% CI 22.5–75.0, p = 0.16). To 
establish OR for good treatment outcome for all locations 
of unruptured GIA rather than using the ICA as the refer-
ence group, we repeated the same model with all other 
locations of unruptured GIA as the reference group ( ta-
ble 4 ).
 Discussion 
 Our systematic review and meta-analysis found that 
the chances of good outcome after surgical or endovascu-
lar GIA treatment mainly depend on patient age and GIA 
location rather than on the type of treatment conducted. 
Overall PGO ranged above 80%, both for endovascular 
and surgical study populations. The chances of good out-
come following endovascular or surgical GIA treatment 
decreased with increasing patient age in all GIA and in 
the subgroup of unruptured GIA. Unruptured GIA of the 
ICA were more likely to show good treatment outcome 
than unruptured GIA in the posterior circulation. These 
findings are in line with data on unruptured non-giant IA 
 [1] .
 Furthermore, we found that GIA treatment outcome 
was not influenced by patient sex, the time of follow-up 
or whether the patients’ clinical status was presented 
based on scores or not. Also, there was no association be-
tween pre-treatment aneurysm rupture and GIA treat-
ment outcome. This contradicts findings on non-giant IA 
 [4] . A possible explanation may be that our analysis only 
included those ruptured GIA that underwent either en-
dovascular or surgical treatment. This means that there 
are no data on patients with a ruptured GIA that were in 
too poor of a clinical condition to receive any sort of treat-
ment. It is therefore highly likely that the subgroup of 
ruptured GIA in our analysis is selected for those patients 
in relatively good neurological condition and, therefore, 
may not represent the full spectrum of patients with rup-
tured GIA.
 Our analysis also included a small cohort of unrup-
tured GIA with combined surgical/endovascular treat-
ment (n = 13). In this group, treatment outcome was 
significantly worse. However, these results have to be 
discussed with caution due to this group’s comparably 
limited case number. Nevertheless, lower chances of 
good outcome after combined GIA treatment may 
also  indicate that those cases were more complex and 
that the initial treatment, be it surgical or endovascular, 
may not have been successful or may have produced 
complications making a second type of intervention 
necessary.
 GIA treatment outcome was also influenced by cer-
tain study characteristics, such as the type of data pre-
sentation and study quality. In studies presenting indi-
vidual patient data, treatment outcome was significant-
ly better than in studies presenting aggregate patient 
data. This disparity was more pronounced in the 
 analysis  of unruptured GIA. Furthermore, studies of 
lower quality reported significantly better treatment 
outcome than high quality studies. Since the majority of 
studies in our analysis was of lower quality, our overall 
findings may be biased toward a better treatment out-
come. This becomes especially evident when comparing 
our overall results to those of the International Study of 
Unruptured Intracranial Aneurysms (ISUIA), which is 
the largest prospective study presenting data on unrup-
tured GIA treatment outcome  [1] . We were able to in-
clude recently updated ISUIA data after a mean FU-T 
of 10 years. ISUIA reached a good treatment outcome 
in 64.7% of GIA after endovascular and 61.6% of GIA 
after surgical treatment. Apart from ISUIA’s relatively 
high study quality another potential explanation for 
ISUIA’s outcome results ranging below our overall re-
sults may be our analysis’ shorter mean FU-T of 16 
months.
Table 4.  OR for good outcome after treatment of unruptured GIA for 
each GIA location with all other GIA locations as reference group
GIA location OR (95% CI) p value
ICA (including PcomA; 153 GIA) 5.15 (2.04–13.00) <0.01
ACA (including AcomA; 17 GIA) 1.10 (0.07–18.48) 0.92
MCA (43 GIA) 2.28 (0.34–15.31) 0.30
Posterior circulation (111 GIA) 0.14 (0.06–0.33) <0.01
 In this sub-analysis of unruptured GIA with individually de-
scribed patient data we included 324 GIA from 48 study popula-
tions [27–67]. Data are presented with 95% CI and p value. 
 PcomA = Posterior communicating artery.
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 Our analysis is the first to systematically evaluate the 
current interdisciplinary GIA literature. Nevertheless, it 
has limitations. The quality of the included studies was 
predominantly low as all of them were purely observa-
tional and non-randomized. Only few studies were of 
prospective design  [1, 19, 27, 39, 44, 57] . Study design-
dependent selection bias can therefore not be ruled out. 
Furthermore, there was substantial variance and het-
erogeneity in the included studies, which also suggests 
that our results should be discussed with caution. Ad-
ditionally, since studies reporting better outcome were 
shown to be more likely to be published, some publica-
tion bias may also confound our overall results  [68] . 
Another limitation is that we allowed different modes 
of outcome measurement. Even though we found that 
treatment outcome did not differ between score-based 
and non–score-based outcome quantification, we can-
not exclude that the type of outcome description may 
have influenced our results. Finally, as all meta-analyses 
are limited by their search terms, so is ours. Our meta-
analysis could have applied more specific search terms 
describing both surgical and endovascular techniques of 
treatment.
 Conclusions 
 In light of the dismal natural history of unruptured 
GIA, the results of our analysis may help elucidate the 
controversial field of endovascular and surgical GIA 
treatment and may therefore be of interest for the ongo-
ing discussion on how to treat unruptured GIA. Our find-
ings support the view that when deciding which type of 
GIA treatment to conduct each case should be discussed 
interdisciplinarily with special focus on patient age and 
GIA location. Since our analysis showed that high quality 
clinical trial evidence on GIA treatment outcome is lack-
ing, we feel that there is a need for a systematic mul-
ticenter approach to collect not only clinical but also
imaging data on GIA. As a first step toward this goal, the 
currently ongoing GIA registry was established as an in-
ternational prospective and retrospective observational 
trial aiming to serve as a platform for future GIA research 
 [69–71] .
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